Danting Zhu

Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)

Antonio Torrelo, Barbara Rewerska, María Laura Galimberti et al. · British Journal of Dermatology · 2023 · 86 citations · Full text

Medicine, Dermatology, Pharmacology +15

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis

Amy S. Paller, Marieke M.B. Seyger, Gabriel A. Magariños et al. · JAMA Dermatology · 2022 · 43 citations · Full text

Medicine, Dermatology, Pediatrics +13

Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials

Sanjay Chabra, B. J. Gill, Gaia Gallo et al. · Advances in Therapy · 2022 · 34 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure

C.E.M. Griffiths, Melinda Gooderham, Jean‐Frédéric Colombel et al. · Dermatology and Therapy · 2022 · 30 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

Atul Deodhar, Andrew Blauvelt, Mark Lebwohl et al. · Arthritis Research & Therapy · 2024 · 25 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16